Skip to main content
. 2021 Apr 3;901:174082. doi: 10.1016/j.ejphar.2021.174082

Fig. 8.

Fig. 8

(A) The ten docked potential inhibitors against SARS-CoV-2 PLPRO from the FDA approved compounds, (B) The 10 potential inhibitors bind to PLPRO, (C) The surface protein with ligands bound to the pocket.